Jian-Guo Zhang1, Yan Ge2, Matt Stead2, Kai Zhang1, Shuang-shuang Yan3, Wei Hu4, Fan-Gang Meng5. 1. Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China. 2. Department of Neurology, Mayo Clinic, Rochester, MN. 3. Institute of Psychology, Chinese Academy of Sciences, Beijing, China. 4. Department of Neurology, Mayo Clinic, Rochester, MN. Electronic address: wei.hu@neurology.ufl.edu. 5. Beijing Neurosurgical Institute, Capital Medical University, Beijing, China. Electronic address: fgmeng@ccmu.edu.cn.
Abstract
OBJECTIVE: To evaluate the effectiveness of deep brain stimulation (DBS) of the globus pallidus internus (GPi) on tic severity and common comorbidities in patients with severe Tourette syndrome that is refractory to pharmacological treatment and psychotherapy. PATIENTS AND METHODS: We retrospectively assessed the long-term clinical outcomes of 13 patients with treatment-refractory Tourette syndrome who underwent DBS targeting the GPi at the Beijing Tiantan Hospital from January 1, 2006, through May 31, 2013. The primary outcome was a change in tic severity as measured by the Yale Global Tic Severity Scale, and the secondary outcome was a change in associated behavioral disorders and mood as measured by the Gilles de la Tourette Syndrome-Quality of Life Scale assessment. RESULTS: Compared with baseline, the mean reduction in the total Yale Global Tic Severity Scale scores at last follow-up (mean, 41.9 months; range, 13-80 months) was 52.1% (range, 4.3%-83.6%), and the mean improvement rates at 1 month, 6 months, 12 months, 18 months, 24 months, 30 months, and 36 or more months were 11.8%, 20.0%, 26.8%, 36.7%, 44.7%, 49.0%, and 56.7%, respectively. A paired-sample t test revealed significant improvement of tic symptoms after 6 months of DBS programming (P<.05). The Gilles de la Tourette Syndrome-Quality of Life Scale score improved by a mean of 45.7% (range, 11.0%-77.2%). CONCLUSION: This study is currently the largest reported GPi DBS case series of patients with treatment-refractory TS with the longest follow-up. Our results support the potential beneficial effect of GPi DBS on disabling tic reduction and improvement of quality of life.
OBJECTIVE: To evaluate the effectiveness of deep brain stimulation (DBS) of the globus pallidus internus (GPi) on tic severity and common comorbidities in patients with severe Tourette syndrome that is refractory to pharmacological treatment and psychotherapy. PATIENTS AND METHODS: We retrospectively assessed the long-term clinical outcomes of 13 patients with treatment-refractory Tourette syndrome who underwent DBS targeting the GPi at the Beijing Tiantan Hospital from January 1, 2006, through May 31, 2013. The primary outcome was a change in tic severity as measured by the Yale Global Tic Severity Scale, and the secondary outcome was a change in associated behavioral disorders and mood as measured by the Gilles de la Tourette Syndrome-Quality of Life Scale assessment. RESULTS: Compared with baseline, the mean reduction in the total Yale Global Tic Severity Scale scores at last follow-up (mean, 41.9 months; range, 13-80 months) was 52.1% (range, 4.3%-83.6%), and the mean improvement rates at 1 month, 6 months, 12 months, 18 months, 24 months, 30 months, and 36 or more months were 11.8%, 20.0%, 26.8%, 36.7%, 44.7%, 49.0%, and 56.7%, respectively. A paired-sample t test revealed significant improvement of tic symptoms after 6 months of DBS programming (P<.05). The Gilles de la Tourette Syndrome-Quality of Life Scale score improved by a mean of 45.7% (range, 11.0%-77.2%). CONCLUSION: This study is currently the largest reported GPi DBS case series of patients with treatment-refractory TS with the longest follow-up. Our results support the potential beneficial effect of GPi DBS on disabling tic reduction and improvement of quality of life.
Authors: Kara A Johnson; Gordon Duffley; Daria Nesterovich Anderson; Jill L Ostrem; Marie-Laure Welter; Juan Carlos Baldermann; Jens Kuhn; Daniel Huys; Veerle Visser-Vandewalle; Thomas Foltynie; Ludvic Zrinzo; Marwan Hariz; Albert F G Leentjens; Alon Y Mogilner; Michael H Pourfar; Leonardo Almeida; Aysegul Gunduz; Kelly D Foote; Michael S Okun; Christopher R Butson Journal: Brain Date: 2020-08-01 Impact factor: 13.501
Authors: Kara A Johnson; Gordon Duffley; Thomas Foltynie; Marwan Hariz; Ludvic Zrinzo; Eileen M Joyce; Harith Akram; Domenico Servello; Tommaso F Galbiati; Alberto Bona; Mauro Porta; Fan-Gang Meng; Albert F G Leentjens; Aysegul Gunduz; Wei Hu; Kelly D Foote; Michael S Okun; Christopher R Butson Journal: Biol Psychiatry Cogn Neurosci Neuroimaging Date: 2020-11-24
Authors: Wissam Deeb; Peter J Rossi; Mauro Porta; Veerle Visser-Vandewalle; Domenico Servello; Peter Silburn; Terry Coyne; James F Leckman; Thomas Foltynie; Marwan Hariz; Eileen M Joyce; Ludvic Zrinzo; Zinovia Kefalopoulou; Marie-Laure Welter; Carine Karachi; Luc Mallet; Jean-Luc Houeto; Joohi Shahed-Jimenez; Fan-Gang Meng; Bryan T Klassen; Alon Y Mogilner; Michael H Pourfar; Jens Kuhn; L Ackermans; Takanobu Kaido; Yasin Temel; Robert E Gross; Harrison C Walker; Andres M Lozano; Suketu M Khandhar; Benjamin L Walter; Ellen Walter; Zoltan Mari; Barbara K Changizi; Elena Moro; Juan C Baldermann; Daniel Huys; S Elizabeth Zauber; Lauren E Schrock; Jian-Guo Zhang; Wei Hu; Kelly D Foote; Kyle Rizer; Jonathan W Mink; Douglas W Woods; Aysegul Gunduz; Michael S Okun Journal: Front Neurosci Date: 2016-04-25 Impact factor: 4.677